Site KR82001

Seoul 137-701

1 studies enrolling now · 16 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Hepatocellular Carcinoma, Advanced Solid Tumors, Allogeneic, Hematopoietic Cell Transplant (HCT), Carcinoma, Transitional Cell, Cytomegalovirus (CMV)-Positive Recipients, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Leukemia, Acute Myeloid (AML), Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC)

Studies at this site

• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder — Recruiting now
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study — Recruiting now
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer — Recruiting now
• A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). — Running, not enrolling
• A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer — Running, not enrolling
• A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer — Running, not enrolling
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation — Completed
• A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Completed
• A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Completed
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) — Completed
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma — Completed
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide — Completed
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder — Completed
• A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) — Completed
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer — Completed